e14a2, e1a2, e19a2, e6a2, e8a2, e13a3, and e14a3. [3] [4] [5] Among these, e13a2 and e14a2 are the major BCR-ABL1 fusion subtypes, occurring in approximately 95% of chronic myeloid leukemia (CML) patients. 5 Because the BCR-ABL1 FG plays a central role in patients with CML by encoding a deregulated tyrosine kinase (the p210 oncoprotein), it has become a target for CML therapy. 6 An international study showed that 70% of patients treated with imatinib achieved complete cytogenetic remission. 7 In recent years, the application of second-generation tyrosine kinase inhibitors (TKIs), such as nilotinib, dasatinib, and bosutinib, has enabled earlier cytogenetic and deeper molecular responses than imatinib. [8] [9] [10] [11] [12] Deep molecular responses in CML provide a rational approach to treatment discontinuation and may predict survival. [13] [14] [15] Therefore, quantification of p210 BCR-ABL1 transcript levels may be increasingly important in the future management of leukemia patients.
The BCR-ABL1 transcript can be sensitively detected by the widely available and sensitive method of reverse transcriptionquantitative polymerase chain reaction (RT-qPCR). However, due to differences in protocols, RT-qPCR is characterized by significant variation and lack of reproducibility between different laboratories. 8 Although efforts to harmonize various laboratory procedures and reporting methods have been made in order to standardize optimal treatment response criteria and facilitate comparisons across laboratories and patients, [16] [17] [18] wide variability in the detection of p210 BCR-ABL1 transcripts remains, 19, 20 hindering clinicians from making appropriate decisions on disease diagnosis and treatment.
External quality assessment (EQA) is an effective tool to compare
results between laboratories and improve laboratory diagnostic capacities. 21 The United Kingdom National External Quality Assessment
Service for Leucocyte Immunophenotyping (UKNEQAS LI) has conducted an international EQA scheme for p210 BCR-ABL1 RT-qPCR analysis for years, covering countries around the world. 19 However, no EQA schemes have been organized in China, and the current performance of p210 BCR-ABL1 testing is unknown. As an EQA provider, the National Center for Clinical Laboratories organized an EQA scheme for p210 BCR-ABL1 testing for the first time, to identify existing problems and ensure the reliability of p210 BCR-ABL1 testing in China.
| MATERIAL S AND ME THODS

| Construction of pACYC-MS2-p210 and CG recombinant plasmids and expression and characteristic evaluation of the corresponding armored RNAs
The target segments of p210 BCR-ABL1 (e14a2) and four common CGs (BCR, GUSB, B2M, and ABL1) (Table S1) were amplified from the cDNA of a patient expressing the BCR-ABL1 e14a2 transcript.
The target segment of p210 BCR-ABL1 was amplified using the forward primer 5′-TCTCTGCACCAAGCTCAAGA-3′ and the reverse primer 5′-CTGCACCAGGTTAGGGTGTT-3′. The four segments of CG were amplified and linked by overlapping PCR at a 1:1 ratio with the primers listed in Figure S1 . Then, two restriction enzyme sites (FseI/PacI) and two 19-nucleotide sequence-specific MS2 cistrons (pac sites) were added directly to the final targeted sequence of p210 BCR-ABL1 and CG using the primers listed in Before the batch production, the p210 and CG armored RNAs must be characteristic of homogeneity between vials and of stability for transportation or storage at different temperatures after they were harvested. Homogeneity and stability tests of the corresponding p210 and CG armored RNAs were conducted following the process presented in Data S1, Section 1.
| Preparation of the p210 QC sample panel
To improve the similarity to clinical samples, we conducted a survey to acknowledge the practical conditions of p210 BCR-ABL1 detection before preparing the QC samples, such as the distribution of p210 BCR-ABL1 and CG transcripts and %BCR-ABL1 ratios (data not shown). Then, variable amounts of p210 armored RNA solutions were diluted with a constant solution of CG armored RNAs to produce a series of p210 QC samples with expected %BCR-ABL1 ratios covering > 10.0% (Level 1(L1)), 1.0%-10.0% (L2), 0.1%-1.0% (L3), 0.01%-0.1% (L4), and <0.01% (L5) intervals according to standardized definitions of molecular responses in CML. 25 Note that we set two pairs of duplicated samples at low and high %BCR-ABL1/CG values to investigate the precision of the detection platform, and one negative sample (phosphate-buffered saline) to investigate laboratory specificity in p210 BCR-ABL1 transcript quantification. Eventually, the p210 BCR-ABL1 QC panels, containing nine positive samples (labeled as 1601, 1603-1610) and one negative sample (1602) in each panel, were prepared and lyophilized (Data S1, Section 2) for long storage.
| Distribution of p210 QC sample panels to participating laboratories
The p210 QC sample panels were shipped to participating laboratories at ambient temperature. The participating laboratories were asked to measure the transcript concentration of QC samples using their routine operating procedures. The following information was requested: date of measurement, resuspension volume, volume of the cDNA synthesis, final volume of the cDNA reaction, the CG, the standards used and their origin, the RNA extraction method, the assay types, instrument models, the raw BCR-ABL1 and CG transcript values, the raw %BCR-ABL1/CG ratio, and the converted %BCR-ABL1/CG ratio. To monitor the effect of transportation on the samples, a blind-mailed sample was sent to a deliberately nonexistent destination and analyzed in our laboratory when it returned using a commercial kit (YUAN BIO, Shanghai, China).
| Data analysis
Statistical analysis was performed using SPSS 17.0 (SPSS Inc., Chicago, IL, USA) or GraphPad Prism 5.0 (GraphPad Prism Software, San Diego, CA, USA). The Gaussian distribution of p210%BCR-ABL1/ CG was tested for normality using the Kolmogorov-Smirnov test.
Differences between the experimental groups were subjected to paired t tests and one-way ANOVA. Pearson's correlation analysis was applied to examine the relationship between high and low p210%BCR-ABL1/CG ratios. P-values < 0.05 were considered statistically significant.
| RE SULTS
| Verification of pACYC-MS2-p210 and CG recombinant plasmids and corresponding armored RNAs
The sequencing results indicated that the targeted segments of p210
BCR-ABL1 and CG were inserted into multiple cloning site 2 of the recombinant plasmid and segments of the four CGs were linked at a 1:1 ratio ( Figure 1A ). Restriction enzyme digestion indicated the correct sizes for the target segments of p210 BCR-ABL1 (1399 bp) and CG (2151 bp; Figure 1B ). After RNA extraction and cDNA synthesis, the p210 and CG armored RNAs could be detected by RT-qPCR using both a commercial kit (YUAN BIO, Shanghai, China) and the LDT ( Figure 1C ).
| Characteristics of p210 and CG armored RNAs
Compared with samples stored at −80°C, no statistical differences were found among each of the four p210 and CG armored RNAs upon their storage at 20°C, 4°C, 25°C, or 37°C for 3, 7, 15, and 30 days;
no differences were also found among the six p210 and CG armored
RNAs upon their storage at −20°C for 1, 2, 3, 4, 5, and 6 months by paired t tests (P > 0.05, Figure 1D ). An interunit homogeneity test
showed that no outlying results were found among eight randomly chosen samples among 200 vials of the p210 and CG armored RNAs by one-way ANOVA (P > 0.05, Figure 1E ).
| Responses from participating laboratories
A total of 80 laboratories participated in the trial, among which 71 reported CG copies, assay configurations in 66 of the laboratories are listed in and qPCR amplification in the same run) for %BCR-ABL1 detection.
In addition, 24 (36.4%) participants could convert their results to the International Scale (IS) using laboratory-specific conversion factors (CFs).
| Performance of participating laboratories
The CV% was calculated with the original detection results of samples. Overall, the difference between the maximum and the minimum CV% was large, ranging from 60.0% to 100.0%, and the percentage of laboratories (%Lab) within 2-, 3-, and 5-fold of the median QC value were 45.5%-80.3%, 68.2%-92.4%, and 72.7%-95.5%, respectively. We also found that the CV% tended to be larger and %Lab within 2-, 3-, and 5-fold of QC tended to be lower when the %BCR-ABL1/CG ratio was<1.0% (Table 2) . In addition, 2 (3.0%) laboratories returned false-positive results and 1 (1.5%) laboratory reported CG > 10 000 copies in the negative sample (1602), suggesting cross-contamination in their daily work.
For positive samples with %BCR-ABL1/CG ratios < 1.0%, 15 falsenegative results were reported from 11(16.7%) laboratories.
| Performance of IS laboratories
Among the 24 laboratories that could convert their results to IS using CFs, the CV% of the unconverted results was 59.7%-106.9%
with an average value of 82.4%; while the CV% of the converted results was 48.4%-80.6% with an average value of 61.6% (Table 2 ).
The unconverted %Lab within 2-, 3-,and 5-fold were 78.2%
(50.0%-87.5%), 87.0% (70.8%-91.7%), and 92.1% (75.0%-100.0%), respectively; by contrast, the converted %Lab within 2-, 3-,and 5-fold were 80.1% (62.5%-91.7%), 89.4% (70.8%-95.8%), and 97.2% (83.3%-100.0%), respectively (Table 2) .
Importantly, as displayed in Figure 2 , we found that the results from majority of laboratories, such as Lab #41 and Lab #55 (marked in yellow), were well converted by CFs, while results from only a few laboratories, such as Lab #43 and Lab #44 (marked in red), were poorly converted, with results deviating from the median value compared to the unconverted result.
| Follow-up of CF changes in IS laboratories
To survey whether changes in the detection system affected the conversion in participating IS laboratories, particularly for Labs #43
and #44, we performed a follow-up on the condition of CF revalidation after the EQA scheme. As shown in CFs were calculated in accordance with the procedure of reference laboratory in China. Labs #43 and #44 were included in these 3
laboratories with changed components of their procedures, and the newly recalculated CFs produced well-converted results. In addition, although no changes occurred in the RT-qPCR platform, Lab #18 did not pass the revalidation, and a new CF was calculated. When using the newly recalculated CFs, the CV% of the converted results can further decrease from 61.6% to 50.6%.
| D ISCUSS I ON
Armored RNA technology is a mature technology that has been used to generate versatile calibrators and control materials for multiple viral assays. 22, [26] [27] [28] In recent years, armored RNA has also been as- international genetic reference panel. 29, 30 In this study, we successfully developed an armored RNA-based p210 QC sample panel and organized the first ever EQA scheme for p210 BCR-ABL1 detection in China.
Compared to cell-based samples, an excellent characteristic of armored RNA-based control materials is their ease of mass production. In this study, to further improve the stability of the armored RNA, we conducted a lyophilization process after the sample panel was prepared, and similar to previous studies, 22, 27, 28 this study has also demonstrated that armored RNA is stable and homogeneous. Moreover, considering that different CGs might be used in different laboratories, we selected four common used CGs Harmonization of the methodology for BCR-ABL1 transcript quantification contributes to decreased variability between laboratories. 17 In this EQA scheme for BCR-ABL1 testing, although 81.8% and 98.5% of the laboratories used a commercial kit (YUANQI BIO, Shanghai, China) and a common CG (ABL1), respectively, the CV% of p210 BCR-ABL1 detection results ranged from 60.0% to 100.0%, slightly exceeding a previous result reported 
| CON CLUS ION
In the EQA scheme for p210 BCR-ABL1 detection in China, an unacceptable level of variability of detection results was found from the participating laboratories, even from the IS laboratories. So we call for an urgent reevaluation of the used methods and the wider standardization for p210 BCR-ABL1 detection via the secondary reference material, which has been developed in China. We believe that this EQA scheme can improve the reproducibility and accuracy of p210 BCR-ABL1 detection to ensure robust laboratory diagnostic capacities in China.
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